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Abstract
Background: Pain is prevalent in myotonic dystrophy 1 (DM1). This study investigated whether CTG repeat size,
disease duration, BMI and motor and psychological function were related to pain in adult patients with DM1, and if
there were gender differences regarding intensity and location of pain.
Method: Cross-sectional design. Pain was investigated in 50 genetically confirmed DM1 patients by combining
clinical assessment and self-reports of pain intensity and locations. Pain scoring results were related to CTG size,
disease duration, muscle strength, walking capacity measured by 6-min walk test, activity of daily life by Katz ADL
Index, respiratory function by Forced Vital Capacity and BMI. In addition, the degree of reported pain was related to
Quality of life measured by WHOQOL-BREF; fatigue was measured by Fatigue severity scale; psychological functions
were measured by Beck Depression Inventory, Beck Anxiety Inventory, IQ and Autism spectrum Quotient.
Results: Pain was reported in 84% of the patients and was significantly correlated with CTG size (r = 0.28 p = 0.050),
disease duration (r = 0.38 p = 0.007), quality of life (r = − 0.37 p = 0.009), fatigue (r = 0.33 p = 0.02) and forced vital
capacity (r = − 0.51, p = 0.005). Significant gender differences, with higher scores for females, were documented. In
male subjects the number of pain locations was significantly correlated with quality of life and the autism quotient.
In females, pain intensity was significantly correlated with activity, respiratory function and BMI.
Conclusions: Pain in DM1 was prevalent, with a strong association to lung function and other aspects of the
disease. Significant gender differences were present for pain intensity and number of pain locations. How pain was
related to other symptoms differed between male and female subjects. Our findings highlight the importance of
assessments of pain in DM1 patients.
Keywords: Myotonic Dystrophy1, Pain, Gender, CTG size, Fatigue, Quality of life, motor function, BMI, FVC,
psychological function, Autism quotient
Introduction
Myotonic Dystrophy type 1 (DM1) is an inherited
neuromuscular disease caused by an unstable CTG nu-
cleotide repeat [1–3]. In addition to skeletal muscles,
several organs and systems, such as the central and per-
ipheral nervous system as well as endocrine organs and
the eyes, may be affected. Cardiac and respiratory in-
volvement is common [4, 5].
Pain in DM1 has mostly been studied by surveys
[6–9]. Jensen et al. found that 60% of DM1 patients
reported chronic pain, most frequently located in the
lower back. Other areas included hands, legs, knees,
ankles and feet, with a mean intensity of 4.5 mea-
sured on a numeric rating scale from 0 to 10 [6].
The authors also found a relationship between pain
intensity and mobility, measured by Brief Pain
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Inventory (BPI) [6, 10]. Another study investigating
pain in DM1 and fascioscapulohumeral muscular dys-
trophy (FSHD), concluded that pain intensity was re-
lated to psychological function [7]. A negative
significant correlation between pain and general men-
tal health measured by Short Form health Survey (SF-
36) in DM1 was also documented by Smith et al. [9].
In another paper, Miró et al. found pain location to
be important for the adjustment to pain, measured by
BPI [8]. Objective testing and measures were lacking
in this study [8]. Furthermore, large fiber neuropathy
has been documented in the DM1 group, with a
higher frequency in men than women, and with an
association with BMI [11, 12] .
Gender has been shown to be related to several symp-
toms documented in patients with DM1. Men have
more frequent cognitive impairment, cardiac and re-
spiratory involvement and severe muscle disability and
are more often socially isolated. Women have more fre-
quent cataract, dysphagia, digestive tract dysfunction, in-
continence, thyroid disorder and obesity [13]. Peric et al.
documented a relationship between pain intensity over
the last few weeks and female gender in DM2, though
they did not observe the same association in DM1 [14].
Gender influencing pain in DM1 has not previously been
reported.
In this cross-sectional study of adult patients with
DM1, we investigated gender differences regarding in-
tensity and location of pain, and whether the degree of
CTG expansion, disease duration, motor and psycho-
logical function were related to pain.
Participants and methods
Recruitment and inclusion
Adult patients with DM1 from two different regions in
Norway were invited to participate in a large cross-
sectional, clinical study [15, 16]. The congenital and
childhood forms of DM1 were not included, due to their
different clinical symptoms [17]. The inclusion period
was between 2012 and 2017. Patients were contacted
through their respective hospitals, the National registry
of neuromuscular diseases and the Norwegian patient
organization. Fifty-five patients with a genetically verified
diagnosis and a typical history of adult form of DM1,
were invited to participate. Of these, 50 patients
accepted.
All patients underwent a neurological examination
with focus on motor function, and all the data included
in this paper were collected during the outpatient visits.
Disease measures: disease duration and CTG size
Disease duration was defined as time between onset of
typical symptoms of DM1, which included myotonia,
cataract, motor impairment or arrhythmia, and study
enrollment [4]. Southern blot analysis for CTG size [1]
was obtained from 49 patients at the time of inclusion.
Pain measures
Patients were instructed to mark and score the inten-
sity of chronic pain, which was defined as pain, ex-
cluding headache, that had been present for at least
3 months. Pain locations were identified using “pain
drawings” (Fig. 1) and the number of pain sites was
added up from these drawings [18]. Pain intensity
was scored by the subjects as the experienced mean
pain intensity based on the numeric rating scale (NRS
0–10): no pain = 0, mild pain = 1–3, moderate pain =
4–6, severe pain = 7–10 [18].
Descriptions of pain quality, which included aching,
deep, burning, lancinating or electrical shock, were col-
lected during history taking. Use of analgesics, physio-
therapy or other pain management strategies, as well as
perceived effect of these strategies, were documented.
Functional measures and questionnaires
Muscle strength was assessed by the Medical Research
Councils (MRC) manual muscle strength test (MMT) 0–
5 [19]. The MRC MMT 0–5 has been criticized for its
unequal categorical width, providing only ordinal data,
and for low discrimination between categories when
used in clinical practice [20, 21]. To counteract these
limitations, we used the MRC 0–3 scale, which has been
recoded from the MRC 0–5 scale according to Van-
houtte et al. [22]. The mean of muscle strength was used
in all analyses and it composed of the muscle strength in
distal extremities (comprising wrist extensors and dorsal
flexors of the ankle), proximal extremities (comprising
shoulder abductors, elbow flexors, elbow extensors, and
hip flexors, knee flexors, knee extensors), and trunk
(comprising the trunk flexors/abdominals and the back
extensors). Due to previously reported symmetry, only
one side was tested [23]. The disease specific Muscular
impairment rating scale MIRS [24] was used to investi-
gate the severity of the muscular impairment. MIRS is a
5-point scale where 1 is no muscular impairment, 2 is
minimal signs, 3 distal weakness, 4 proximal weakness
and 5 severe proximal weakness. The MIRS is reliable
and has been validated, though Mathieu et al. advise
caution when interpreting small samples due to low
interrater reliability [24].
The six-minute walk test (6MWT) was conducted ac-
cording to the American Thoracic Society guidelines
[25]. However, the corridor track in the present study
was 20m long instead of 30 [26, 27]. Mean 6-min walk-
ing distance (6MWD) for healthy men between 20 and
50 years is 638 ± 44 m. Mean 6MWD for healthy women
is 593 ± 57 m. These values are dependent on age and
BMI in healthy populations [26]. Percent-predicted value
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for the 6MWD was calculated using reference equations
as described by Enright et al.: men:1.140 m – (5.61 x
BMI)- (6.94 x age), women: 1.017 m-(6.24 x BMI) –
(5.83 x age) = [28].
The Katz Index of Independence in Activities of
Daily Living was assessed by interview, to evaluate
personal independence in activity of daily living [29,
30]. Forced Vital Capacity (FVC) values [31] and in-
formation on possible co-morbidities such as diabetes
and thyroid dysfunction and symptomatic medication
for myotonia were collected from the patients’ med-
ical files. The fatigue severity scale (FSS) was used to
measure general fatigue [32–35]. Scores > 5 on FSS
are regarded as high levels of fatigue [32]. Height and
weight were measured and body mass index (BMI)
[36] was calculated.
Cognitive measures and psychological questionnaires
General cognitive function (IQ) was assessed with the
Wechsler Adult Intelligence Scale (WASI II) [37]. Symp-
toms of anxiety and depression were assessed with the
Beck Anxiety Inventory (BAI) [38] and the Beck Depres-
sion Inventory (BDI) [39]. The Autism Spectrum Quo-
tient (AQ) [40] was used for assessing the amount of
ASD symptoms. And finally, for quality of life, the WHO
quality of life-BREF (WHOQOL-BREF) questionnaire
was utilized [41].
Statistics
The SPSS 25 (IBM Corporation Armonk, NY, USA) was
used for calculations. Normally distributed variables
were presented with mean, standard deviation (SD) and
range. Non-normally distributed variables were pre-
sented with median and range. Assessments of group
differences were performed with students t-tests and
Mann Whitney u test when appropriate. Effect sizes
(Cohens d) were calculated using the online social sci-
ence statistics service: http://www.soscistatistics.com/
effectsize/Default3.aspx.
Correlations were performed with parametric and
nonparametric tests when normal distributions were not
present. P-values were set at two tailed = < 0.05, and
Bonferroni corrections were used for adjustments of
multiple comparisons for the question of gender differ-
ences regarding pain intensity measured by NRS and
number of pain locations (NPL). Exact p-values were re-
ported when between 0.05–0.001. All analyses of the
pain measures and other disease characteristics are de-
scriptive correlations, and not Bonferroni corrected due
to their explorative nature. In order to control for group
differences in CTG between men and women, a linear
regression model with forced entry method was done for
NRS, AQ, FVC and 6MWT. Assumptions for linear re-
gression were met. We calculated 50 patients to be suffi-
cient for 90% power to answer the questions of gender
differences in pain.
Fig. 1 Pain-distribution (%), all participants
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Guidelines
This study has been performed in accordance with the
declaration of Helsinki. All methods and reporting were
performed in accordance with the STROBE guideline.
Results
Participant characteristics
Fifty genetically verified adult DM1 patients were in-
cluded. The patients had mild to severe reduction of
muscle strength in trunk and distal extremities, while
the proximal extremity muscle groups were mildly to
moderately affected (Table 1). The CTG repeat size was
distributed as follows in the 50 patients: 3 patients (6%)
had a very small repeat size (50–100 CTG repeats), 6 pa-
tients (12%) had a small repeat size (101–200 CTG re-
peats); 24 patients (49%) had a medium repeat size
(201–700 CTG repeats); and 16 patients (33%) had a
large repeat size (> 700 CTG repeats); None of the pa-
tients were diagnosed with diabetes mellitus or thyroid
dysfunction, or used medication for myotonia. Patient
characteristics are summarized in Table 1.
Percent-predicted 6MWD (n45): 56.78%, SD: 16.1,
range:17.76–101.64, median 58.97.
Women (n23): mean 57.23, SD: 18.77, range: 22.11–
101.64, median 51.29.
Men (n22): mean 56.30. SD: 13.15, range: 17.76–75.60,
median: 60.81.
Not all participants completed all questionnaires.
When N is below 50, exact number is reported. Five pa-
tients were not able to perform the 6MWT because of
the need for a wheel chair. Some did not complete cog-
nitive assessments and the psychological questionnaires
due to personal reasons, mostly lack of time. With re-
gard to questionnaires, the lowest number of completed
questionnaires was 83% (BAI). In addition, 81% of pa-
tients completed the IQ assessment. One patient did not
have a new analysis of CTG repeats, and was conse-
quently excluded from analyses which included this
Table 1 Characteristics of 50 patients with DM1
Characteristics Mean, SD,
(Range)
Men (n 24) Women (n 26) Difference between men
and women/Cohens d
Age, years 40.1, SD: 12.6. (19–
63)
37, SD: 13.8 (19–63) 43, SD: 10.7 (23–62) ns
CTG kb N49 1.8, SD: 1.4
(0.230–5.4)
1.3, SD: 1.1 (0.270–4.7) n24 2.3, SD: 1.5 (0.230–5.4) n25 P = 0.008/0.8
Disease duration, years 19.0, SD: 10.0 (5–
42)
16.4, SD: 9.6 (5–42) 21.5, SD: 9.7 (6–40) ns
Mean strength of trunk muscles
(MTT 0–3)
1.7, SD: 0.5 (1–2.6) 1.8, SD: 0.5 (1–2.6) 1.6, SD: 0.4 (1–2.3) ns
Mean strength of distal extremity
(MTT 0–3)
2.3, SD: 0.5 (1.5–3) 2.3, SD: 0.5 (1.5–3) 2.3, SD: 0.5 (1.5–3) ns
Mean strength of proximal extremity (MTT
0–3)
2.6, SD: 0.3 (2–3) 2.7, SD: 0.3 (2–3) 2.6, SD: 0.3 (2–3) ns
Fatigue (FSS) Questionnaire N48 4.8, SD: 1.3 (2–7) 4.5, SD: 1.6 (2–7) n23 4.9, SD: 1 (3–7) n25 Ns / 0.33







Katz ADL Questionnaire [6.0] (3–6) [5.5] (3–6) [6.0] (4–6) ns
Autism quotient index (AQ) Questionnaire
N47
17.0, SD: 6.1 (6–32) 19.4, SD: 5.4 (11–32) n21 15.0, SD: 6.1 (6–28) n 26 p = 0.014 / 0.75
IQ N41 92.0, SD: 14.2
(64–137)
92.5, SD:17 (64–137) n20 91.5, SD: 11.4 (71–114) n21 ns/ 0.06
Anxiety (BAI) Questionnaire N43 [4.0] (0–26) [3.0] (0–26) n22 [4.5] (0–23) n 22 ns
Depression (BDI) Questionnaire N44 [8.0] (0–37) [7.0] (0–19) n21 [8.0] (0–37) n 23 ns
Respiration spirometry (FVC%) N 29 71.7, SD: 18.8
(25–103)
76.4, SD: 14.0 (55–103) n13 67.9, SD: 21.6 (25–99) n16 ns/ 0.77




91.3, SD: 12.4 (71–115) n24 88.2, SD:14.1 (59–114) n26 ns/ 0.23
BMI 26.6, SD: 6.6 (15–
53)
26.3, SD: 5.5 (15–34) 26.9, SD: 7.5 (17–53) ns/0.09
Mean, [Median] SD, (min/max) are presented. Exact p-levels are given for differences < 0.05 between men and women and the Cohens d effect size is reported
DM1 Myotonic Dystrophy type 1, CTG Cytosine, Thymine, Guanine, MMT Manual Muscle strength test, FSS Fatigue Severity Scale, 6MWT Six-minute walk test, Katz
ADL Assessment of Activities of Daily Living, IQ Intelligence quotient, BAI Becks Anxiety Inventory, BDI Becks Depression Inventory, FVC Forced Vital Capacity,
WHOQOL BREF World health Organization Quality of Life Assessment, BMI Body mass index
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measure. All patients completed the pain measures. De-
tails of muscle impairment severity are summarized in
Table 2.
The functions measured did not differ between male
and female patients. Neither did BMI. However, some
Cohens d effect sizes are > 0.5, which may indicate group
differences for 6MWT, FVC and AQ in a larger group.
A possible contribution of CTG size compared to gender
for FVC, AQ and 6MWT was investigated using linear
regression models including gender and CTG as inde-
pendent variables, see Table 1 Additional file 1. The
models show that CTG had a stronger contribution than
gender to FVC and 6MWT, whilst for AQ, gender had a
stronger contribution compared to CTG (R: 0.34, p =
0.066, Beta CTG = -0.068, p = 0.67. Beta Gender = 0.31,
p = 0.053).
Pain
Frequency, intensity and locations
Chronic pain was reported in 84% of the patients, and
32% of these reported severe pain (NRS 7–10). Mean
pain intensity was moderate (NRS = 4.6), and the mean
number of pain locations (NPL) was 3.2. For gender dif-
ferences, see Table 3. Pain locations were widespread
and symmetrically distributed. The most frequently re-
ported pain locations were the lumbar and cervical parts
of the spine and the palmar sides of the hands (Fig. 1).
Pain qualities
Different pain qualities were described. Most of the pa-
tients reporting pain described it as aching or deep or
both (62%). 22% reported a burning or lancinating pain
quality in their feet, distal part of their legs and hands.
Analgesics, physiotherapy and other pain intervention
Of the 42 patients reporting pain, 16 (38%) used anal-
gesic. The following medication was used: Paracetamol
was used by 11 patients (26%), four used opioids (9%),
Gabapentin was used by three persons (7%), cannabi-
noids were used by three persons (7%), antidepressants
by one person (2%). Five (12%) patients were on more
than one type of analgesic.
Seventeen (40%) of the patients reporting pain used
physiotherapy consisting of exercise, musculoskeletal
mobilization and massage. Acupuncture and
manipulation were also used as symptomatic treatment.
Of these, 6 patients (14%) combined analgesics and
physiotherapy.
All patients experienced some pain relief, while 5
(12%) reported very good pain relief.
Pain correlated to CTG size, age, disease duration and
somatic and psychological symptoms
Pain intensity was significantly correlated to CTG size
(r = 0.28, p = 0.050), disease duration (r = 0.38, p = 0.007),
quality of life (r = − 37, p = 0.009) and fatigue (r = 0.33,
p = 0.02). The number of pain locations was correlated
to disease duration (r = 36, p = 0.01) and quality of life
(r = − 0.33, p = 0.01). No significant correlation between
the pain measures and age, anxiety, depression, the aut-
ism quotient, IQ, muscle strength, MIRS, 6MWT, Katz
ADL or BMI were found. The only significant correlation
between pain and function measures was between NRS
and FVC which were negatively correlated (r = − 0.51,
p = 0.005).
Pain differences in men and women
Pain frequency
Chronic pain was reported in 71% of the men and 96%
of the women. Moderate pain was present in 46% of
women and 25% of men, and the percentage of women
reporting severe pain was more than twice that in men
(42% vs. 20, see Fig. 2).
The distribution of pain locations differed between
men and women. However, only pain in the back was
significantly more frequent in women. 88% of the
women reported back pain compared to 50% of the men
(Fisher’s exact test p = 0.005).
Pain intensity and number of pain locations
NRS, as well as NPL were significantly different in men
and women (Table 3).
In order to control for the group difference between
gender in CTG size, one linear regression was con-
ducted with NRS as a dependent variable. CTG size
and gender were independent variables: R = 0.45, p =
0.003, only gender had an independent contribution:
β: 0.39, p = 0.008.
Table 2 MIRS distribution
MIRS MIRS mean MIRS 1 MIRS 2 MIRS 3 MIRS 4 MIRS 5
N 50 3.1, SD:1.1(1–5) 4% 30% 24% 34% 8%
Men n 24 3, SD:1.1(1–5) 8.3% (n2) 29.2% (n7) 25% (n6) 29.2% (n7) 8.3% (n2)
Women n26 3.2, SD: 1 (2–5) 0 30.8% (n8) 23% (n6) 38.5% (n10) 7.7% (n2)
Mean, SD, and range are reported for the total MIRS in the whole group and in men and women. Distribution to the different MIRS categories, is presented as
number and percentage of patients for the whole sample and for men and women
MIRS Muscular impairment rating scale
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Correlations between pain, CTG size, disease duration and
symptoms in men and women
The correlation between NRS and disease duration was
significant, but only in the female group (rho 0.41, p =
0.40). Furthermore, pain was related to different symp-
toms and findings in men compared to women, see
Table 4.
In male subjects, NPL was significantly correlated
to quality of life and to measures of socio-cognitive
function (AQ). In female subjects, NRS was related to
motor function measures, Katz ADL, FVC and to
BMI. There was no significant association between
pain and MMT.
Discussion
In this study we found a high frequency of chronic pain
with a mean value of moderate intensity in adult patients
with DM1. Furthermore, pain was widespread and sym-
metrical, with 3.2 as the mean number of pain locations.
In our sample of subjects, only NRS was significantly re-
lated to size of CTG repeats, FVC and fatigue. However,
both NRS and the NPL were significantly correlated to
disease duration and quality of life.
A novel finding was that there were gender differences
for pain in DM1 patients. Pain was more frequent, had a
greater intensity and was more widespread in female
compared to male subjects. How pain is correlated to
other symptoms also differs. In men, pain was correlated
to the autism quotient (AQ), and quality of life (WHO-
QOL-BREF). In women, pain was related to disease dur-
ation, activity (Katz ADL), respiratory function (FVC)
and BMI.
Frequency, intensity and location
Most (84%) of the patients reported chronic pain, and
35% reported severe pain intensity (7–10 on NRS). This
is consistent with findings from previous pain studies of
DM1 where frequencies between 60 and 88% are de-
scribed [6, 9, 14]. This frequency is higher than that
which has been reported in general in Scandinavian pop-
ulations. In Norway, the prevalence of chronic pain is re-
ported to be 24% [42]. A review from Sweden and
Denmark documented a prevalence of 16 and 18% re-
spectively in non-cancer populations [43]. DM1 affects
many organs and most patients can be characterized as
multimorbid. Nociceptive pain may likely be present and
caused by DM1 myopathy, where muscle tissue over
time is replaced by fat infiltration, which leads to loss of
function and strength [16, 44–46]. An additional cause
may be neuropathic pain, since polyneuropathy is docu-
mented in DM1 groups without comorbidity like dia-
betes or thyroid dysfunction [12]. The quality
descriptions of pain may differ in neuropathic compared
to nociceptive pain. Pain quality may therefore, to a cer-
tain extent, differentiate causes of pain. 22% of the pa-
tients with pain in this study reported burning or
lancinating pain, possibly indicating neuropathic pain.
The high number of pain locations documented in
this study possibly reflects the distribution of muscu-
lar affection in DM1 as described in the literature
[15, 23]. The most frequent pain locations reported
by our patients were the lower back, the neck and
the ventral side of the hands. Chronic low back pain
is frequent in several populations [47]. Our findings
indicate that chronic low back pain is even more fre-
quent among adult DM1 patients than in mixed pop-
ulations, an observation which was also documented
in a study by Miro and co-authors [8, 47]. This might
be caused by the trunk muscle impairments in DM1,
which also includes severe atrophy of the lower
erector spinae muscles [15, 16, 44, 45, 48]. This atro-
phy may not only cause loss of strength, but also im-
pair co-contraction and muscle recruitment, and may
lead to decreased stability of the trunk. Trunk stabil-
ity is a prerequisite for mobility and for protecting
the spine and extremities against injuries and possible
pain [49]. In DM1, low back pain may be related to
mechanical impairment and thereby nociceptive pain
mechanisms such as increased weight on joints and
the remaining skeletal muscle tissue.
Table 3 Mean pain intensity and number of pain locations in the whole group and in men and women
Pain measures Whole group N50 Men (n24) Women (n26) Difference between men and women
Mean NRS 4.6, SD: 2.7 (0–9) [5] 3.2, SD: 2.7 (0–8) 5.8, SD: 2.0 (0–9) asympt. p = 0.001
Mean NPL 3.2, SD: 2.4 (0–8) [3] 2.3, SD: 2.3 (0–6) 4.0, SD: 2.2 (0–8) asympt. p = 0.01
Mean, Standard deviation: (SD) and (range) are reported. Pain intensity and number of pain locations are both sig. Different for men and women. Median:[].
Bonferroni correction p = 0.01
Fig. 2 Distribution of pain intensity in men and women
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In addition, weakness of the neck muscles, leading
to inability to lift the head from a supine position, is
a core clinical feature in DM1 [4]. Neck muscle atro-
phy may lead to problems with stabilizing the head
and neck, thereby causing pain. Hand pain could be
explained by the well-known myopathy in distal ex-
tremities in DM1 [4]. Indeed, in one case report, the
patients’ presenting symptom of DM1 was pain in the
hands [50].
Pain, DM1 duration and CTG
Pain intensity was related to CTG size and disease
duration. DM1 is a progressive disorder, and the se-
verity of the disease depends to a high degree on the
number of CTG repeats, which probably explains this
finding [51]. Peric et al. also found that pain intensity
was related to disease duration [14]. During progres-
sion of DM1, CTG levels increase, several organs and
tissues may become affected, muscle strength de-
creases and motor and respiratory impairments in-
crease [4]. As muscle strength decreases, activities of
daily life become more challenging and possibly de-
mand muscle activity closer to the maximal strength
and endurance of the individual patients. Jensen et al.
investigated pain intensity in groups with different
mobility limitations. They found that pain intensity
was significantly higher in DM1 patients with the
most impaired mobility, in need of assistive devises
for mobility, such as canes, a wheelchair or another
person [6]. Pain in another neuromuscular disorder,
congenital myopathy, is may be triggered by ADL ac-
tivities [52]. Furthermore, because muscle work is
dependent upon lung function, respiratory deficit may
impair motor function even more. Also, in a study of
DM1 mice, peripheral nerve affection was found to be
related to CTG size [53]. Neuropathy may influence
muscle function, both strength, endurance and timing
may become impaired [54]. It is therefore possible
that the impact DM1 progression and high levels of
CTG repeats have on different organs, may lead to
pain.
Pain and anxiety, depression, fatigue and QoL
In contrast to the findings in previous studies on neuro-
muscular disorders, including DM1, we found no signifi-
cant correlations between pain measures and anxiety or
depression measured by BAI and BDI. This could be due
to differences in study design, patient populations and
measures [6, 7].
However, several findings in our study imply that
pain has an impact on how patients feel and think.
Both quality of life and the degree of fatigue were re-
lated to pain. Our documentation of an association
between pain and fatigue is in line with studies in
other patient populations [55]. Fatigue is also related
to disease duration in DM1 [9, 56]. In addition, pain
is shown to be predictive of fatigue in a longitudinal
study on DM1 [57]. The relationship between pain
and quality of life in DM1 is in line with findings in
other neuromuscular disorders [8, 14, 58].
Pain and gender
Gender differences in pain are well documented in gen-
eral populations, with women being more frequently af-
fected [42, 59]. We now document the same
phenomenon in DM1. Female DM1 patients report a
higher intensity and number of pain locations than male
patients. The frequency of pain located in the lower back
is also significantly higher in DM1 women. This may be
related to the DM1 myopathy leading to lower muscle
strength in women compared to men [16, 51]. Others
have pointed out that the myopathy in DM1 mimics
what is seen in sarcopenia [60]. In the elderly, a certain
loss of muscle mass (sarcopenia) is related to chronic
low back pain [61]. However, an association between
chronic low back pain and the cross-sectional area of
muscles is not clearly documented in healthy popula-
tions, whereas an association between pain and disability
has been [62].
Interestingly, BMI did not differ in men and women.
However, BMI was only related to pain in women. That
pain is related to BMI is well documented in general
populations, and mechanical impairments, as well as
Table 4 Correlations between pain and measures of function and quality of life in men and women
Measures Men Women
NRS /Pain Intensity Number of pain locations NRS/Pain Intensity Number of pain locations
Quality of life / WHO QOL-BREF rho = − 0.51 p = 0.012 ns ns
Autism spectrum /AQ ns rho = 0.47 p = 0.03 ns ns
Respiration / FVC ns ns rho = −0.78 p = 0.0003 ns
ADL Katz ns ns rho = −0.39 p = 0.048 ns
BMI ns ns rho = 0.48 p = 0.016 ns
Exact p-levels are reported when < = 0.05
ns not significant = p > 0.05
Rho for Spearman’s correlation
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inflammation caused by the presence of adipose tissue
are suggested as possible mechanisms for this [63]. In
DM1, muscles become atrophied and replaced by fat in-
filtration, and muscle size is significantly smaller in fe-
male as compared to male patients [16]. One could
speculate that inflammatory mechanisms, as well as
mechanical causes may play a role in explaining the gen-
der differences in DM1 patients.
The relation between pain and activity measured by
Katz ADL seen in women might be explained by the
lower level of muscle strength in DM1 women [51]. A
relationship between pain and the most affected muscu-
lar regions is reported in FSHD [58]. However, we did
not find an association between muscle strength and
pain. This may be caused by the MMT measures not be-
ing sensitive enough for detecting smaller changes in
muscle strength. Another explanation may be that DM1
women report higher pain intensity than DM1 men.
Pain intensity > 4 on the Visual Analogue Scale is, to a
lesser degree, related to activity [64]. The Katz ADL is
composed of physical activity involving flexion, rotation
and extension of the spine as well as gross and fine
motor movements, which may be avoided to prevent or
minimize pain.
We find lower levels of FVC in women than men,
and a significant correlation between pain and FVC
in women. This could be caused by women having a
more restrictive respiratory pattern compared to
men. The low FVC seen in women may be influ-
enced by DM1 myopathy in the trunk muscles [16,
51]. Trunk muscles are important in respiration,
and the rectus abdominus especially for forced ex-
piration [16, 65]. Severe impairment of the cranial
abdominal rectus has been documented in DM1 by
our study group, as well as others [16, 44, 45]. FVC
may thus be a predictor of a myopathic and im-
paired rectus muscles function, leading to pain. The
relation between lung function and pain may also
be caused by hypoventilation. Hypoventilation in-
creases the probability of fatigue and reduced
muscle endurance [66, 67].
The association between men’s pain and quality of life
has previously been reported in a study on patients with
chronic pain [68]. Given the same degree of chronic pain
in male and female patients, that study also reported a
significantly lower quality of life in men than in women
[68]. This relationship may therefore be a general gender
difference and not specific for DM1.
For the first time, a relation between symptoms of aut-
ism spectrum disease (ASD) and pain in DM1 is investi-
gated. In previous pain studies on individuals diagnosed
with autism, both hypo- and hypersensitivity are re-
ported [69, 70]. Whether the correlation between pain
and ASD symptoms identified in the current study are
due to a common cause, or a result of abnormal self-
reporting in individuals with high rates of ASD symp-
toms, is not known. It is possible that male patients be-
come more attentive to their pain to the degree that it
affects or impairs their social communicative function.
However, the relationship observed may also reflect a
particular disease trajectory in men where ASD symp-
toms co-occur with pain. Social communicative function
such as ASD has been shown to be related to both
neurophysiological and structural CNS abnormalities in
DM1 [71, 72]. Another study on symptoms in DM1
found higher levels of CNS symptoms in male patients
compared to female [13]. This might be in line with the
latter explanation, but the relation between pain and so-
cial communicative function needs to be further ex-
plored in DM1.
Men and women differed significantly in CTG triplet
size, and this could contribute to the gender differences
in reported pain. However, in the regression model in-
cluding CTG size and gender, only gender had a signifi-
cant contribution. This strengthens the conclusion that
there is a gender difference regarding pain in DM1, and
that we as clinicians have to approach this symptom dif-
ferently dependent on the sex of the patient.
Strength and limitations
The main strength of our study is that we combine sub-
jective and objective measures, in a well-defined patient
group with genetic verification of the diagnosis for all
participants. Another strength is that the clinical exam-
ination and measurements of the CTG size were both
performed at the time of the pain assessments. Further-
more, patients were included in a broad assessment
study and therefore probably not biased towards partici-
pating in a pain study only. This may have strengthened
the study’s external validity to the general DM1 adult
population. In addition, for the main question of gender
differences, the sample size is large enough to make con-
clusions. A limitation is the cross-sectional design which
does not allow for conclusions regarding which direc-
tions the relations go. Furthermore, caution must be
made for some of the conclusions, given the explorative
nature of some of the questions. And finally, since pain
is subjectively measured by NRS and NPL, we cannot
exclude gender differences in reporting style. We did not
use a validated pain questionnaire like Brief Pain Inven-
tory. This should be done in future studies investigating
gender differences and pain in DM1. However, both the
pain drawing and our measurement of pain intensity are
the same as were used in BPI. The difference in CTG ex-
pansion size between men and women in our population
represents a bias in our sample. Why the included
women have more CTG repeats than men is not known,
but may be due to the fact that mortality is higher in
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more severely affected DM1 men compared to women
[13]. Another reason may be that DM1 men are more
isolated and might therefore lack the personal support
needed to respond to such an invitation [13].
Conclusion
Pain in adult forms of DM1 is frequent and widespread.
Mean pain intensity is moderate. Furthermore, pain is
related to respiration, disease duration, quality of life, fa-
tigue and CTG size. Pain in DM1 is influenced by gen-
der and significant gender differences are present for
pain intensity and number of pain locations. How pain is
related to function is also different between men and
women. In women, pain seems to be primarily related to
respiration, BMI and motor function, while in men pain
is more associated with psychological functioning.
Our findings highlight the importance of assessments
of pain in DM1 patients, and associated symptoms.
These gender-dependent relations between pain and
function are important, and should be investigated in
future research.
Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s12883-021-02124-9.
Additional file 1: Table 1. Regression models controlling for CTG size
and gender.
Acknowledgements
We thank Tormod Hagen MD, and Gunnar Hansen MD, for facilitating this
project, expert assistance and medical examinations of the participants.
Conflict of interest
The authors state no conflict of interest.
Authors’ contributions
GS, ED, and KØ conceived and designed the study. GS and KØ analysed the
data. All authors interpreted the data, reviewed the manuscript and proved
the final manuscript.
Funding
This study was supported by the Sophies Minde Foundation and Vestre
Viken Health Trust.
Availability of data and materials
The datasets generated and/or analysed during the current study are not
publicly available due to the consent form used, some limitation of data
sharing may apply, but are available from the corresponding author on
reasonable request.
Declarations
Ethics approval and consent to participate
This study was approved by the Regional Committee for Medical and Health
Research Ethics (REC), South East of Norway (# 2011/2186). All patients gave




The authors declare that they have no competing interests.
Author details
1Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 2Department
of Neurology, Rheumatology and Rehabilitation, Drammen Hospital, Vestre
Viken Health Trust, Drammen, Norway. 3Department of Clinical Medicine, The
Arctic University of Norway, Tromsø, Norway. 4Section of Clinical
Neurophysiology, University Hospital of North Norway, Tromsø, Norway. 5K.G.
Jebsen Center for Neurodevelopmental Disorders, Institute of Clinical
Medicine, University of Oslo, Oslo, Norway. 6NevSom, Department of Rare
Disorders, Oslo University Hospital, Oslo, Norway. 7Institute of Health and
Society, University of Oslo, Oslo, Norway. 8Department of Neurology, Oslo
University Hospital, Oslo, Norway.
Received: 30 October 2020 Accepted: 16 February 2021
References
1. Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H,
et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide
(CTG) repeat at the 3′ end of a transcript encoding a protein kinase family
member. Cell. 1992;68(4):799–808.
2. Yum K, Wang ET, Kalsotra A. Myotonic dystrophy: disease repeat range,
penetrance, age of onset, and relationship between repeat size and
phenotypes. Curr Opin Genet Dev. 2017;44:30–7. https://doi.org/10.1016/j.
gde.2017.01.007.
3. Mahadevan M, Tsilfidis C, Sabourin L, Shutler G, Amemiya C, Jansen G, et al.
Myotonic dystrophy mutation: an unstable CTG repeat in the 3′
untranslated region of the gene. Science. 1992;255(5049):1253–5.
4. Harper PS, Van Engelen BG. Myotonic dystrophy: present management,
future therapy. Oxford: Oxford University Press; 2004.
5. Lo Mauro A, Aliverti A. Physiology of respiratory disturbances in muscular
dystrophies. Breathe. 2016;12(4):318–27. https://doi.org/10.1183/20734735.
012716.
6. Jensen MP, Hoffman AJ, Stoelb BL, Abresch RT, Carter GT, McDonald CM.
Chronic pain in persons with myotonic dystrophy and facioscapulohumeral
dystrophy. Arch Phys Med Rehabil. 2008;89(2):320–8. https://doi.org/10.1016/
j.apmr.2007.08.153.
7. Miró J, Raichle KA, Carter GT, O'Brien SA, Abresch RT, McDonald CM, et al.
Impact of biopsychosocial factors on chronic pain in persons with myotonic
and facioscapulohumeral muscular dystrophy. Am J Hosp Palliat Care. 2009;
26(4):308–19. https://doi.org/10.1177/1049909109335146.
8. Miró J, Gertz KJ, Carter GT, Jensen MP. Pain location and intensity impacts
function in persons with myotonic dystrophy type 1 and
facioscapulohumeral dystrophy with chronic pain. Muscle Nerve. 2014;49(6):
900–5. https://doi.org/10.1002/mus.24079.
9. Smith AE, McMullen K, Jensen MP, Carter GT, Molton IR. Symptom burden
in persons with myotonic and facioscapulohumeral muscular dystrophy. Am
J Phys Med Rehabil. 2014;93(5):387–95. https://doi.org/10.1097/phm.
0000000000000032.
10. Poquet N, Lin C. The Brief Pain Inventory (BPI). J Physiother. 2016;62(1):52.
https://doi.org/10.1016/j.jphys.2015.07.001.
11. Hermans MC, Faber CG, Vanhoutte EK, Bakkers M, De Baets MH, de Die-
Smulders CE, et al. Peripheral neuropathy in myotonic dystrophy type 1. J
Peripher Nerv Syst. 2011;16(1):24–9. https://doi.org/10.1111/j.1529-8027.2011.
00313.x.
12. Peric S, Stojanovic VR, Nikolic A, Kacar A, Basta I, Pavlovic S, et al. Peripheral
neuropathy in patients with myotonic dystrophy type 1. Neurol Res. 2013;
35(4):331–5. https://doi.org/10.1179/1743132812y.0000000144.
13. Dogan C, De Antonio M, Hamroun D, Varet H, Fabbro M, Rougier F, et al.
Gender as a Modifying Factor Influencing Myotonic Dystrophy Type 1
Phenotype Severity and Mortality: A Nationwide Multiple Databases Cross-
Sectional Observational Study. PLoS One. 2016;11(2):e0148264. https://doi.
org/10.1371/journal.pone.0148264.
14. Peric M, Peric S, Rapajic N, Dobricic V, Savic-Pavicevic D, Nesic I, et al.
Multidimensional aspects of pain in myotonic dystrophies. Acta Myol. 2015;
34(2–3):126–32.
15. Solbakken G, Orstavik K, Hagen T, Dietrichs E, Naerland T. Major involvement
of trunk muscles in myotonic dystrophy type 1. Acta Neurol Scand. 2016.
https://doi.org/10.1111/ane.12565.
16. Solbakken G, Bjornara B, Kirkhus E, Nguyen B, Hansen G, Frich JC, et al. MRI
of trunk muscles and motor and respiratory function in patients with
Solbakken et al. BMC Neurology          (2021) 21:101 Page 9 of 11
myotonic dystrophy type 1. BMC Neurol. 2019;19(1):135. https://doi.org/1
0.1186/s12883-019-1357-8.
17. Thornton CA. Myotonic dystrophy. Neurol Clin. 2014;32(3):705–19, viii.
https://doi.org/10.1016/j.ncl.2014.04.011.
18. Haefeli M, Elfering A. Pain assessment. Eur Spine J. 2006;15(Suppl 1):S17–24.
https://doi.org/10.1007/s00586-005-1044-x.
19. Mendell JR, Florence J. Manual muscle testing. Muscle Nerve. 1990;
13(Suppl):S16–20. https://doi.org/10.1002/mus.880131307.
20. Brandsma JW, Schreuders TA, Birke JA, Piefer A, Oostendorp R. Manual
muscle strength testing: intraobserver and interobserver reliabilities for the
intrinsic muscles of the hand. J Hand Ther. 1995;8(3):185–90.
21. Merlini L. Measuring muscle strength in clinical trials. Lancet Neurol. 2010;
9(12):1146; author reply −7. https://doi.org/10.1016/s1474-4422(10)70285-4.
22. Vanhoutte EK, Faber CG, van Nes SI, Jacobs BC, van Doorn PA, van
Koningsveld R, et al. Modifying the Medical Research Council grading
system through Rasch analyses. Brain. 2012;135(Pt 5):1639–49. https://doi.
org/10.1093/brain/awr318.
23. Bouchard JP, Cossette L, Bassez G, Puymirat J. Natural history of skeletal
muscle involvement in myotonic dystrophy type 1: a retrospective study in
204 cases. J Neurol. 2015;262(2):285–93. https://doi.org/10.1007/s00415-014-
7570-x.
24. Mathieu J, Boivin H, Meunier D, Gaudreault M, Begin P. Assessment of a
disease-specific muscular impairment rating scale in myotonic dystrophy.
Neurology. 2001;56(3):336–40.
25. CoPSfCPFL ATS. ATS statement: guidelines for the six-minute walk test. Am J
Respir Crit Care Med. 2002;166(1):111–7. https://doi.org/10.1164/ajrccm.1
66.1.at1102.
26. Chetta A, Zanini A, Pisi G, Aiello M, Tzani P, Neri M, et al. Reference values
for the 6-min walk test in healthy subjects 20-50 years old. Respir Med.
2006;100(9):1573–8. https://doi.org/10.1016/j.rmed.2006.01.001.
27. Kierkegaard M, Tollback A. Reliability and feasibility of the six minute walk
test in subjects with myotonic dystrophy. Neuromuscul Disord. 2007;17(11–
12):943–9. https://doi.org/10.1016/j.nmd.2007.08.003.
28. Enright PL, Sherrill DL. Reference equations for the six-minute walk in
healthy adults. Am J Respir Crit Care Med. 1998;158(5 Pt 1):1384–7. https://
doi.org/10.1164/ajrccm.158.5.9710086.
29. Sonn U. Longitudinal studies of dependence in daily life activities among
elderly persons. Scand J Rehabil Med Suppl. 1996;34:1–35.
30. Kierkegaard M, Harms-Ringdahl K, Holmqvist LW, Tollbäck A.
Functioning and disability in adults with myotonic dystrophy type 1.
Disabil Rehabil. 2011;33(19–20):1826–36. https://doi.org/10.3109/096382
88.2010.549287.
31. Morris JF. Spirometry in the evaluation of pulmonary function. West J Med.
1976;125(2):110–8.
32. Lerdal A, Wahl A, Rustoen T, Hanestad BR, Moum T. Fatigue in the general
population: a translation and test of the psychometric properties of the
Norwegian version of the fatigue severity scale. Scand J Public Health. 2005;
33(2):123–30. https://doi.org/10.1080/14034940410028406.
33. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale.
Application to patients with multiple sclerosis and systemic lupus
erythematosus. Arch Neurol. 1989;46(10):1121–3. https://doi.org/10.1001/a
rchneur.1989.00520460115022.
34. de Groot IJ, Voet NB, van Middendorp H, Knoop HJ, Rahbek J, van Engelen
BG. 184th ENMC international workshop: pain and fatigue in neuromuscular
disorders: 20-22 may 2011, Naarden, the Netherlands. Neuromuscul Disord.
2013;23(12):1028–32. https://doi.org/10.1016/j.nmd.2013.06.370.
35. Laberge L, Dauvilliers Y, Bégin P, Richer L, Jean S, Mathieu J. Fatigue and
daytime sleepiness in patients with myotonic dystrophy type 1: to lump or
split? Neuromuscul Disord. 2009;19(6):397–402. https://doi.org/10.1016/j.
nmd.2009.03.007.
36. WHO. Global database on Body Mass Index http://apps.who.int/bmi/index.
jsp (2019). Accessed 23052018 Accessed 10.2. 2019.
37. McCrimmon AW, Smith AD. Review of the Wechsler abbreviated scale of
intelligence, second edition (WASI-II). J Psychoeduc Assess. 2012;31(3):337–
41. https://doi.org/10.1177/0734282912467756.
38. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical
anxiety: psychometric properties. J Consult Clin Psychol. 1988;56(6):893–7.
https://doi.org/10.1037//0022-006x.56.6.893.
39. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for
measuring depression. Arch Gen Psychiatry. 1961;4:561–71. https://doi.org/1
0.1001/archpsyc.1961.01710120031004.
40. Baron-Cohen S, Wheelwright S, Skinner R, Martin J, Clubley E. The autism-
spectrum quotient (AQ): evidence from Asperger syndrome/high-
functioning autism, males and females, scientists and mathematicians. J
Autism Dev Disord. 2001;31(1):5–17. https://doi.org/10.1023/a:10056534114
71.
41. Hanestad BR, Rustoen T, Knudsen O Jr, Lerdal A, Wahl AK. Psychometric
properties of the WHOQOL-BREF questionnaire for the Norwegian general
population. J Nurs Meas. 2004;12(2):147–59. https://doi.org/10.1891/jnum.2
004.12.2.147.
42. Rustoen T, Wahl AK, Hanestad BR, Lerdal A, Paul S, Miaskowski C. Prevalence
and characteristics of chronic pain in the general Norwegian population.
Eur J Pain. 2004;8(6):555–65. https://doi.org/10.1016/j.ejpain.2004.02.002.
43. Harker J, Reid KJ, Bekkering GE, Kellen E, Bala MM, Riemsma R, et al.
Epidemiology of chronic pain in Denmark and Sweden. Pain Res Treat.
2012;2012:371248. https://doi.org/10.1155/2012/371248.
44. Park D, Park JS. Quantitative assessment of trunk muscles involvement in
patients with myotonic dystrophy type 1 using a whole body muscle
magnetic resonance imaging. Eur Neurol. 2017;77(5–6):238–45. https://doi.
org/10.1159/000460291.
45. Kornblum C, Lutterbey G, Bogdanow M, Kesper K, Schild H, Schroder R,
et al. Distinct neuromuscular phenotypes in myotonic dystrophy types 1
and 2 : a whole body highfield MRI study. J Neurol. 2006;253(6):753–61.
https://doi.org/10.1007/s00415-006-0111-5.
46. Díaz-Manera J, Llauger J, Gallardo E, Illa I. Muscle MRI in muscular
dystrophies. Acta Myol. 2015;34(2–3):95–108.
47. Meucci RD, Fassa AG, Faria NM. Prevalence of chronic low back pain:
systematic review. Rev Saude Publica. 2015;49. https://doi.org/10.1590/
s0034-8910.2015049005874.
48. Degardin A, Morillon D, Lacour A, Cotten A, Vermersch P, Stojkovic T.
Morphologic imaging in muscular dystrophies and inflammatory
myopathies. Skelet Radiol. 2010;39(12):1219–27. https://doi.org/10.1007/s002
56-010-0930-4.
49. Borghuis J, Hof AL, Lemmink KA. The importance of sensory-motor control
in providing core stability: implications for measurement and training.
Sports Med. 2008;38(11):893–916. https://doi.org/10.2165/00007256-20083
8110-00002.
50. Mughal F, Rashid A, Mishra RC. A case of unusual hand pain in general
practice. Bmj. 2015;351:h5005. https://doi.org/10.1136/bmj.h5005.
51. Gagnon C, Petitclerc E, Kierkegaard M, Mathieu J, Duchesne E, Hebert LJ. A
9-year follow-up study of quantitative muscle strength changes in myotonic
dystrophy type 1. J Neurol. 2018;265(7):1698–705. https://doi.org/10.1007/
s00415-018-8898-4.
52. Werlauff U, Højberg A, Firla-Holme R, Steffensen BF, Vissing J. Fatigue in
patients with spinal muscular atrophy type II and congenital myopathies:
evaluation of the fatigue severity scale. Qual Life Res. 2014;23(5):1479–88.
https://doi.org/10.1007/s11136-013-0565-8.
53. Panaite PA, Kielar M, Kraftsik R, Gourdon G, Kuntzer T, Barakat-Walter I.
Peripheral neuropathy is linked to a severe form of myotonic dystrophy in
transgenic mice. J Neuropathol Exp Neurol. 2011;70(8):678–85. https://doi.
org/10.1097/NEN.0b013e3182260939.
54. White CM, Pritchard J, Turner-Stokes L. Exercise for people with peripheral
neuropathy. Cochrane Database Syst Rev. 2004;4:Cd003904. https://doi.org/1
0.1002/14651858.CD003904.pub2.
55. Meeus M, Nijs J, Meirleir KD. Chronic musculoskeletal pain in patients with
the chronic fatigue syndrome: a systematic review. Eur J Pain. 2007;11(4):
377–86. https://doi.org/10.1016/j.ejpain.2006.06.005.
56. Schillings ML, Kalkman JS, Janssen HM, van Engelen BG, Bleijenberg G,
Zwarts MJ. Experienced and physiological fatigue in neuromuscular
disorders. Clin Neurophysiol 2007;118 2:292–300; doi: https://doi.org/10.101
6/j.clinph.2006.10.018.
57. Kalkman JS, Schillings ML, Zwarts MJ, van Engelen BG, Bleijenberg G. The
development of a model of fatigue in neuromuscular disorders: a
longitudinal study. J Psychosom Res 2007;62 5:571–579; doi: https://doi.
org/10.1016/j.jpsychores.2006.11.014.
58. Morís G, Wood L, FernáNdez-Torrón R, González Coraspe JA, Turner C,
Hilton-Jones D, et al. Chronic pain has a strong impact on quality of life in
facioscapulohumeral muscular dystrophy. Muscle Nerve. 2018;57(3):380–7.
https://doi.org/10.1002/mus.25991.
59. FHI. Chronic Pain. 2019.
60. Mateos-Aierdi AJ, Goicoechea M, Aiastui A, Fernández-Torrón R, Garcia-Puga
M, Matheu A, et al. Muscle wasting in myotonic dystrophies: a model of
Solbakken et al. BMC Neurology          (2021) 21:101 Page 10 of 11
premature aging. Front Aging Neurosci. 2015;7:125. https://doi.org/10.3389/
fnagi.2015.00125.
61. Sakai Y, Matsui H, Ito S, Hida T, Ito K, Koshimizu H, et al. Sarcopenia in
elderly patients with chronic low back pain. Osteoporos Sarcopenia. 2017;
3(4):195–200. https://doi.org/10.1016/j.afos.2017.09.001.
62. Ranger TA, Cicuttini FM, Jensen TS, Heritier S, Urquhart DM. Paraspinal
muscle cross-sectional area predicts low back disability but not pain
intensity. Spine J. 2019;19(5):862–8. https://doi.org/10.1016/j.spinee.2018.12.
004.
63. Chin SH, Huang WL, Akter S, Binks M. Obesity and pain: a systematic review.
Int J Obes. 2020;44(5):969–79. https://doi.org/10.1038/s41366-019-0505-y.
64. Paraschiv-Ionescu A, Perruchoud C, Rutschmann B, Buchser E, Aminian K.
Quantifying dimensions of physical behavior in chronic pain conditions. J
Neuroeng Rehabil. 2016;13(1):85. https://doi.org/10.1186/s12984-016-0194-x.
65. Welch JF, Kipp S, Sheel AW. Respiratory muscles during exercise: mechanics,
energetics, and fatigue. Curr Opin Physiol. 2019;10:102–9. https://doi.org/1
0.1016/j.cophys.2019.04.023.
66. Böing S, Randerath WJ. Chronic hypoventilation syndromes and sleep-
related hypoventilation. J Thorac Dis. 2015;7(8):1273–85. https://doi.org/10.3
978/j.issn.2072-1439.2015.06.10.
67. Sansone VA, Gagnon C. 207th ENMC workshop on chronic respiratory
insufficiency in myotonic dystrophies: management and implications for
research, 27-29 June 2014, Naarden, the Netherlands. Neuromuscul Disord.
2015;25(5):432–42. https://doi.org/10.1016/j.nmd.2015.01.011.
68. Rovner GS, Sunnerhagen KS, Björkdahl A, Gerdle B, Börsbo B, Johansson F,
et al. Chronic pain and sex-differences; women accept and move, while
men feel blue. PLoS One. 2017;12(4):e0175737. https://doi.org/10.1371/
journal.pone.0175737.
69. Whitney DG, Shapiro DN. National Prevalence of pain among children and
adolescents with autism Spectrum disorders. JAMA Pediatr. 2019;173(12):
1203–5. https://doi.org/10.1001/jamapediatrics.2019.3826.
70. Clarke C. Autism Spectrum disorder and amplified pain. Case Rep Psychiatry.
2015;2015:930874. https://doi.org/10.1155/2015/930874.
71. Serra L, Cercignani M, Bruschini M, Cipolotti L, Mancini M, Silvestri G, et al. "I
Know that You Know that I Know": Neural Substrates Associated with Social
Cognition Deficits in DM1 Patients. PLoS One. 2016;11(6):e0156901. https://
doi.org/10.1371/journal.pone.0156901.
72. Serra L, Bianchi G, Bruschini M, Giulietti G, Domenico CD, Bonarota S, et al.
Abnormal cortical thickness is associated with deficits in social cognition in
patients with myotonic dystrophy type 1. Front Neurol. 2020;11:113. https://
doi.org/10.3389/fneur.2020.00113.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Solbakken et al. BMC Neurology          (2021) 21:101 Page 11 of 11
